BAYN.DE stock trades at €37.78 on XETRA in Germany, up 1.02% intraday on 06 Mar 2026 with 5,145,257 shares traded so far. Today’s range is €36.30–€38.44, putting the price below the 50-day average of €42.29 but above the 200-day average of €31.86. Investors are watching volume and legal headlines that moved shares earlier this week, while traders test short-term support and resistance levels.

BAYN.DE stock intraday price action and volume

Intraday activity shows Bayer AG (BAYN.DE) at €37.78, a rise of €0.38 from the prior close of €37.40. Volume of 5,145,257 is 1.35x the average volume, signalling higher trader interest. Day high is €38.44 and day low €36.30, so short-term traders are focused on the €36.30 support and the €38.44 intraday resistance.

BAYN.DE stock fundamentals and valuation

Bayer reports market cap €37.11B, EPS -0.20, and a negative P/E of -188.87, reflecting recent net losses and litigation charges. Key ratios: PB 1.25, P/S 0.81, and free cash flow yield 10.61%. Compared with the Healthcare sector average P/E 30.04, BAYN.DE looks cheaper on book and sales metrics but faces profitability and litigation risks.

BAYN.DE stock technicals and trading signals

Technicals show an RSI of 30.65 and MACD histogram -1.01, indicators of oversold conditions and negative momentum. The 50-day average is €42.29 and 200-day average €31.86, so the trend is mixed. Traders can watch RSI and the €36.30 support for a short-term buy signal or a break below the 200-day slope for a wider sell trigger.

BAYN.DE stock news, catalysts and immediate drivers

Recent headlines cite widening net losses linked to Roundup litigation and a small sales rise in Pharma and Crop Science; that news has driven intraweek volatility. Read coverage at Investing.com Bayer price history and the WSJ report on litigation charges WSJ. Near-term catalysts include earnings on 11 May 2026 and any legal settlement updates.

BAYN.DE stock Meyka grade and model forecast

Meyka AI rates BAYN.DE with a score out of 100: 68.87/100, Grade B, Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of €36.85, a quarterly target of €59.74, and a one-year projection of €16.08; forecasts are model-based projections and not guarantees.

BAYN.DE stock risks, opportunities and analyst context

Main risks are litigation expense volatility, negative EPS momentum, and a high net debt-to-EBITDA metric of 5.53. Opportunities include Crop Science exposure, Pharma pipeline collaborations, and a PB near 1.25 that may appeal to value buyers. Analysts vary: a conservative near-term target around €45.00, base €60.00, and downside scenarios to €25.00 reflect the range of outcomes.

Final Thoughts

Short-term action in BAYN.DE stock centers on legal headlines, above-average volume, and mixed technical signals. At €37.78 on XETRA, Bayer sits below the 50-day average but above the 200-day average, creating a trading range. Meyka AI’s forecast model projects a monthly level of €36.85 (implied downside -2.46% from €37.78) and a quarterly target of €59.74 (implied upside +58.16%). The one-year projection is €16.08 (implied downside -57.44%), underscoring forecast dispersion. Meyka AI-powered market analysis platform flags the stock as Grade B (68.87/100) and suggests a HOLD, balancing recovery potential in Crop Science and Pharma against litigation and profitability risks. Traders should watch the €36.30 support and volume spikes; longer-term investors should weigh free cash flow strength against net debt and legal uncertainty. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.